Aquestive Therapeutics Submits NDA for Anaphylm

Aquestive Therapeutics ( (AQST) ) just unveiled an update.

Aquestive Therapeutics reported its first quarter 2025 financial results and provided a business update, highlighting the submission of a New Drug Application (NDA) for Anaphylm, an oral sublingual film for severe allergic reactions. The company plans a potential U.S. launch in early 2026, subject to FDA approval, and is focusing resources on this launch, pausing other projects. Financially, the company saw a 28% decrease in total revenues compared to the first quarter of 2024, primarily due to a decline in manufacture and supply revenue. The net loss increased to $22.9 million, driven by higher selling, general, and administrative expenses.

The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.

Spark’s Take on AQST Stock

According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.

Aquestive Therapeutics is facing significant financial challenges, including persistent net losses and negative equity, which are major concerns. While there is some technical and product pipeline optimism, negative valuation metrics and mixed earnings guidance limit the stock’s appeal.

To see Spark’s full report on AQST stock, click here.

More about Aquestive Therapeutics

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines that improve patients’ lives through innovative science and delivery technologies. The company specializes in developing oral film-based products and is engaged in the pharmaceutical industry with a market focus on treatments for severe allergic reactions, seizures, and other conditions.

Average Trading Volume: 1,392,324

Technical Sentiment Signal: Sell

Current Market Cap: $277.1M

Find detailed analytics on AQST stock on TipRanks’ Stock Analysis page.